A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
12/2002
12/05/2002	WO2002096896A1 Biologically active methylene blue derivatives
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096887A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096498A2 Use of sheets for producing body compresses and a pre-product and device therefor
12/05/2002	WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096447A2 Pharmaceutical preparation containing active ingredients extracted from the plants centella asiatica, mahonia aquifolium and viola tricolor
12/05/2002	WO2002096444A2 Plumbago europaea constituents for use against psoriasis and hair loss
12/05/2002	WO2002096434A1 Plaster preparation
12/05/2002	WO2002096429A1 Agent for external therapy of psoriasis and method for producing said agent
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096374A2 Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
12/05/2002	WO2002096370A1 Pack based on water-soluble nonwoven fabric
12/05/2002	WO2002096367A2 Targeted multivalent macromolecules
12/05/2002	WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096221A2 Skin diet
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002064088A3 Pharmaceutical composition for the treatment of alopecia
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002047728A3 Treatment of posterior capsule opacification
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183400 Composition for topical application comprising at least one hydroxystilbene and at least one polyol to solubilize the hydroxystilbene
12/05/2002	US20020183399 Method and compositions for treating rosacea
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183381 Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
12/05/2002	US20020183377 Use of melatonin for treating androgenetic and diffuse alopecia
12/05/2002	US20020183346 Tricyclic androgen receptor modulator compounds and methods
12/05/2002	US20020183339 Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient
12/05/2002	US20020183338 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
12/05/2002	US20020183326 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183316 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
12/05/2002	US20020183314 For therapy of acne, male- pattern baldness, sexual dysfunction, impotence, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers
12/05/2002	US20020183297 Pharmaceutical composition for the treatment of alopecia
12/05/2002	US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002	US20020183282 For skin, muscle, ocular or gastric mucosal healing
12/05/2002	US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020183255 Use of KPV tripeptide for dermatological disorders
12/05/2002	US20020183248 Locally administering to a cutaneous site at least one lectin capable of interfering with the infective capability of a pathogenic microorganism toward dermal tissue, in an amount effective to diminish infective capability microorganism
12/05/2002	US20020183242 Peptide antiangiogenic drugs
12/05/2002	US20020182683 Vascular endothelial growth factor 2
12/05/2002	US20020182650 Inhibitors of binding between proteins and macromolecular ligands
12/05/2002	US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182265 Lubricious coatings for substrates
12/05/2002	US20020182262 Based on hypochlorous acid; used in the treatment of leg ulcers or other open wounds.
12/05/2002	US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini.
12/05/2002	US20020182213 Method for the treatment of fibrosis
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020182156 Contacting the melanocyte with a melanin synthesis inhibiting amount of a fatty acid synthase (FAS) inhibitor (such as cerulenin) to reduce melanin synthesis in the melanocyte
12/05/2002	US20020182155 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same
12/05/2002	CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	CA2448956A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448562A1 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448345A1 Stable liquid formulations of antibodies
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448305A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	CA2446723A1 Antibodies that immunospecifically bind to trail receptors
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/04/2002	EP1262184A1 Compositions comprising S-tofisopam and use of these compositions for the preparation of a medicament for the treatment or prevention of convulsions or seizures
12/04/2002	EP1262177A2 Medical use of thyromimetic compounds to treat hair loss and compositions
12/04/2002	EP1262169A2 Skin anti-ageing composition

1 ... 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 ... 1065